During the past decade, CH Rene Dubos; Oncologie conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 1 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "CH Rene Dubos; Oncologie" are "Non-Squamous Non-Small Cell Lung Cancer" (2 trials) and "Breast Cancer" (1 trials). Many other conditions were trialed in "CH Rene Dubos; Oncologie" in a lesser frequency.

Most popular intervention types in "CH Rene Dubos; Oncologie" are "Drug" (1 trials). Other intervention types were less common.

The name of intervention was led by "Bevacizumab" (1 trials), "Docetaxel" (1 trials), "Erlotinib" (1 trials) and "Pemetrexed" (1 trials). Other intervention names were less common.

The vast majority of trials in "CH Rene Dubos; Oncologie" are 2 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "CH Rene Dubos; Oncologie". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in CH Rene Dubos; Oncologie, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in CH Rene Dubos; Oncologie, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".